Announcements Trials
Browse Landscape

Phase

Phase 2 29Phase 1 27Phase 3 8Phase 1/2 4Phase NA 2Phase EARLY_PHASE1 1Phase 4 1Phase 2/3 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Glioblastoma 8Recurrence 3Astrocytoma 3Gliosarcoma 2Spinal Cord Neoplasms 1Small Cell Lung Carcinoma 1Pituitary Neoplasms 1Oligodendroglioma 1Non Small Cell Lung Cancer Metastatic 1Melanoma 1Medulloblastoma 1Glioma 1Ependymoma 1Brain Neoplasms 1Advanced Glioblastoma 1

Interventions

Radiotherapy 2vocimagene amiretrorepvec 1Vincristine 1Temozolomide 1Radiation 1Procarbazine 1Lomustine 1DNA 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2/3 × Oligodendroglioma × Temozolomide × Clear all
NCT04105374 2026-05-07

Testing the Addition of an Anti-cancer Viral Gene Therapy, Toca 511/Toca FC, to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed Glioblastoma

NRG Oncology

Phase 2/3 Withdrawn
CNS

Astrocytoma, Glioblastoma, Oligodendroglioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡